A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

This Study is
No Longer Enrolling

Details
Age

Child

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 20-2471

More information available at ClinicalTrials.gov: NCT04557735

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers